Related Experiment Video
Updated: Oct 5, 2025
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
A Pediatric Case of Sensory Predominant Guillain-Barré Syndrome Following COVID-19 Vaccination
Yunsung Kim1, Zahra Zhu1, Puneet Kochar2
1Penn State College of Medicine, Hershey, PA, USA.
Insights
A rare case of Guillain-Barre syndrome (GBS) occurred in a teen after the Pfizer-BioNTech COVID-19 vaccine. This report details sensory GBS symptoms following vaccination in a 16-year-old female.
Area of Science:
- Neurology
- Vaccinology
- Immunology
Background:
- Widespread COVID-19 vaccination necessitates monitoring for adverse events.
- Thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barre syndrome (GBS), and myocarditis are identified potential vaccine-related conditions in adults.
- Pediatric GBS cases post-COVID-19 vaccination are rarely reported.
Observation:
- A 16-year-old female developed sensory predominant GBS after receiving the Pfizer-BioNTech COVID-19 vaccine.
- The patient presented with ascending numbness and paresthesia in her upper and lower extremities.
- This case highlights a rare neurological side effect in adolescents.
Findings:
- The case describes sensory GBS following the Pfizer-BioNTech COVID-19 vaccine in a pediatric patient.
- The symptoms included bilateral ascending numbness and paresthesia.
- This adds to the limited data on GBS in adolescents post-vaccination.
Implications:
- Further investigation into rare neurological complications of COVID-19 vaccines in pediatric populations is warranted.
- Understanding vaccine-related GBS is crucial for vaccine safety monitoring and public health.
- This case contributes to the ongoing surveillance of adverse events following immunization (AEFI).
Abstract:
Over six billion doses of Coronavirus Disease 2019 (COVID-19) vaccines have been administered worldwide. Amidst the global COVID-19 vaccination campaign, vaccine-related side effects are of ongoing concern and investigation. According to the Centers for Disease Control and Prevention (CDC) and the United States Department of Health and Human Services, three main conditions in adults have surfaced in association with receiving the COVID-19 vaccines. These include thrombosis with thrombocytopenia syndrome (TTS), a rare syndrome involving venous or arterial thrombosis and thrombocytopenia, Guillain-Barre syndrome (GBS), and myocarditis. While a number of GBS cases in adults have been published, to our knowledge, only one pediatric case of COVID-19 vaccine-related GBS has been reported. Herein we describe a case of sensory predominant GBS following the Pfizer-BioNTech COVID-19 vaccine in a 16-year-old female presenting with bilaterally ascending upper and lower extremity numbness and paresthesia.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
